Holen Sie sich die Stockscreener-App
136.67
0.51%
-0.70
Handel nachbörslich:
136.67
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt ILMN?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$137.37
Offen:
$139.38
24-Stunden-Volumen:
1.13M
Relative Volume:
0.61
Marktkapitalisierung:
$21.68B
Einnahmen:
$4.39B
Nettoeinkommen (Verlust:
$-1.58B
KGV:
-13.72
EPS:
-9.96
Netto-Cashflow:
$546.00M
1W Leistung:
-0.01%
1M Leistung:
-4.51%
6M Leistung:
+14.00%
1J Leistung:
+2.33%
1-Tages-Spanne:
$136.49
$140.33
1-Wochen-Bereich:
$131.75
$153.06
52-Wochen-Spanne:
$100.08
$156.66
Illumina Inc Stock (ILMN) Company Profile
Firmenname
Illumina Inc
Sektor
Branche
Telefon
(858) 202-4500
Adresse
5200 ILLUMINA WAY, SAN DIEGO, CA
Vergleichen Sie ILMN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ILMN
Illumina Inc
|
136.67 | 21.68B | 4.39B | -1.58B | 546.00M | -9.96 |
|
TMO
Thermo Fisher Scientific Inc
|
559.65 | 214.07B | 42.37B | 6.14B | 7.78B | 15.95 |
|
DHR
Danaher Corp
|
238.36 | 172.16B | 23.74B | 3.89B | 4.98B | 5.24 |
|
A
Agilent Technologies Inc
|
147.36 | 42.09B | 6.51B | 1.29B | 1.37B | 4.42 |
|
IQV
Iqvia Holdings Inc
|
197.36 | 35.82B | 15.32B | 1.41B | 1.96B | 7.62 |
|
IDXX
Idexx Laboratories Inc
|
419.26 | 34.33B | 3.84B | 866.24M | 792.60M | 10.37 |
Illumina Inc Stock (ILMN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-11 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-11-12 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2024-10-17 | Hochstufung | HSBC Securities | Hold → Buy |
| 2024-08-28 | Hochstufung | Argus | Hold → Buy |
| 2024-08-16 | Hochstufung | Daiwa Securities | Neutral → Buy |
| 2024-08-14 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2024-08-14 | Hochstufung | TD Cowen | Hold → Buy |
| 2024-07-10 | Hochstufung | Citigroup | Neutral → Buy |
| 2024-06-03 | Fortgesetzt | Jefferies | Hold |
| 2024-01-16 | Herabstufung | HSBC Securities | Buy → Hold |
| 2024-01-04 | Herabstufung | TD Cowen | Outperform → Market Perform |
| 2023-12-18 | Hochstufung | Scotiabank | Sector Perform → Sector Outperform |
| 2023-12-15 | Hochstufung | Bernstein | Underperform → Mkt Perform |
| 2023-12-14 | Eingeleitet | Guggenheim | Buy |
| 2023-12-14 | Eingeleitet | Stephens | Overweight |
| 2023-12-13 | Eingeleitet | Wolfe Research | Outperform |
| 2023-12-12 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2023-12-11 | Hochstufung | Citigroup | Sell → Neutral |
| 2023-11-10 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2023-09-28 | Eingeleitet | Bernstein | Underperform |
| 2023-07-05 | Fortgesetzt | JP Morgan | Neutral |
| 2023-01-25 | Herabstufung | Argus | Buy → Hold |
| 2023-01-05 | Eingeleitet | Scotiabank | Sector Perform |
| 2022-12-12 | Herabstufung | Citigroup | Neutral → Sell |
| 2022-12-07 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2022-10-04 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2022-09-28 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2022-08-25 | Eingeleitet | Credit Suisse | Neutral |
| 2022-07-13 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2022-01-18 | Hochstufung | Stifel | Hold → Buy |
| 2022-01-11 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2022-01-07 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2022-01-06 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2022-01-06 | Fortgesetzt | Piper Sandler | Overweight |
| 2021-10-15 | Fortgesetzt | Cowen | Outperform |
| 2021-08-19 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2021-06-01 | Hochstufung | Evercore ISI | Underperform → In-line |
| 2021-03-31 | Herabstufung | Atlantic Equities | Overweight → Neutral |
| 2021-03-31 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2021-03-03 | Eingeleitet | Barclays | Underweight |
| 2020-12-22 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2020-12-17 | Hochstufung | BTIG Research | Neutral → Buy |
| 2020-10-13 | Herabstufung | Guggenheim | Buy → Neutral |
| 2020-09-30 | Eingeleitet | Atlantic Equities | Overweight |
| 2020-09-29 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2020-09-22 | Herabstufung | Stifel | Buy → Hold |
| 2020-09-22 | Herabstufung | UBS | Buy → Neutral |
| 2020-09-21 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-09-21 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-09-09 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2020-08-07 | Herabstufung | Evercore ISI | In-line → Underperform |
| 2020-08-07 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2020-07-07 | Herabstufung | Guggenheim | Buy → Neutral |
| 2020-04-24 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-04-21 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-01-08 | Eingeleitet | Wells Fargo | Underweight |
| 2020-01-07 | Eingeleitet | Citigroup | Buy |
| 2020-01-02 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2019-11-15 | Eingeleitet | Stifel | Buy |
| 2019-10-25 | Eingeleitet | Guggenheim | Buy |
Alle ansehen
Illumina Inc Aktie (ILMN) Neueste Nachrichten
Cancer Biopsy Market Size is Expected to Reach USD 60.92 Billion by 2033, Growing at a CAGR of 7.81%: Straits Research - GlobeNewswire Inc.
Illumina, Inc.'s (NASDAQ:ILMN) Price Is Out Of Tune With Revenues - Simply Wall St
Illumina, Inc. (NASDAQ:ILMN) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Microfluidics Market Poised for Substantial Growth (2025-2032) | PerkinElmer, Agilent Technologies, Inc., Illumina. - openPR
Key Trends in the Bioinformatics Market with Insights from - openPR
Sax Wealth Advisors LLC Invests $561,000 in Illumina, Inc. (NASDAQ:ILMN) - MarketBeat
Avanza Fonder AB Buys Shares of 17,599 Illumina, Inc. (NASDAQ:ILMN) - MarketBeat
Illumina Partners NVIDIA for Genomic Advancements, ILMN Stock Climbs - MSN
JP Morgan 2025: analysts remain doubtful of Illumina’s growth - MSN
Gateway Investment Advisers LLC Raises Position in Illumina, Inc. (NASDAQ:ILMN) - MarketBeat
Video: The first NovaSeq X in the Benelux region is a “game changer” - Illumina
Bioinformatics Market Analysis, Size, Share, and Growth - openPR
Illumina, Inc. (NASDAQ:ILMN) Shares Sold by Sicart Associates LLC - MarketBeat
Whole Exome Sequencing Market Overall Study Report 2025-2032 | - openPR
Global Single Cell Bioinformatics Software and Service Market - openPR
Why Illumina (ILMN) is Poised to Beat Earnings Estimates Again - Yahoo Finance
Beech Hill Advisors Inc. Boosts Stake in Illumina, Inc. (NASDAQ:ILMN) - MarketBeat
Illumina, Inc. (NASDAQ:ILMN) Short Interest Update - MarketBeat
USA Financial Formulas Acquires New Position in Illumina, Inc. (NASDAQ:ILMN) - MarketBeat
Lab-on-a-chip and Microarrays (Biochip) Market Future - openPR
Biomarker Research Services Market Projected To Witness Substantial Growth, 2025-2032:Abbott Laboratories, - EIN News
Illumina (NASDAQ:ILMN) Trading Up 5.7%Time to Buy? - MarketBeat
Illumina Announces Preliminary Unaudited Financial Results for Fourth Quarter and Fiscal Year 2024 and Provides Preliminary Outlook for Fiscal Year 2025 - Longview News-Journal
Illumina, Inc. (NASDAQ:ILMN) Shares Acquired by CCLA Investment Management - MarketBeat
Illumina, Nvidia Launch AI-Based Genomics Partnership - Genetic Engineering & Biotechnology News
Future-Proofing Growth of DNA Data Storage Market, Size, - openPR
Molecular Diagnostics Market Size, Share & Business Opportunities forecast by 2031 | F. Hoffmann-La Roche Ltd, - EIN News
RNA Sequencing Market 2024-2031 Global Industry Analysis, - openPR
Illumina CEO Highlights Genomics Future and Nvidia Partnership at JPMorgan Health-Care Conference - HPBL
Genomic Cancer Testing Market Future Business Opportunities - openPR
Illumina partners with Nvidia on AI-powered genomic sequencing - MSN
Illumina reports preliminary Q4 results, provides 2025 expectations - MSN
Illumina CEO Thaysen on Nvidia Partnership, Genomics, M&A - Marketscreener.com
Nvidia Announces Partnerships with Mayo Clinic, Illumina & More at JPM25 - Dealbreaker
Illumina Raises Q4 Revenue Outlook To $1.10 Billion, Exceeding Street Expectations; Sees Solid Margins - Benzinga
Illumina (NASDAQ:ILMN) Issues FY 2024 Earnings Guidance - MarketBeat
Illumina posts modest Q4 revenue growth, anticipates 2025 rise - Investing.com
Illumina (NASDAQ:ILMN) Issues Q4 Earnings Guidance - MarketBeat
Illumina stock falls on 2025 outlook miss By Investing.com - Investing.com Australia
Illumina, Nvidia collaborate to decode biology and propel precision health - Yahoo Finance
Illumina stock falls on 2025 outlook miss - Investing.com
Truveta sells stakes to Regeneron, Illumina in deal to build genetic database - MSN
Nvidia (NVDA) Expands Healthcare Presence with Illumina Partnership - TipRanks
Illumina (NASDAQ:ILMN) Trading 5.7% HigherWhat's Next? - MarketBeat
Illumina partners with NVIDIA for advanced genomics analysis By Investing.com - Investing.com Canada
Morgan Stanley Cuts Illumina (NASDAQ:ILMN) Price Target to $150.00 - MarketBeat
Illumina, Nvidia team to use AI in foundation models - MedTech Dive
Illumina and Regeneron invest $139.5m in Truveta to build largest genetic database - Yahoo Finance
Illumina and NVIDIA Just Dropped a Genomics Bombshell - GuruFocus.com
Nvidia partners with Illumina, IQVIA use generative AI to boost drug discovery (NVDA:NASDAQ) - Seeking Alpha
Nvidia Partners With Illumina and Mayo Clinic in Health Push - Bloomberg
Finanzdaten der Illumina Inc-Aktie (ILMN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.09%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):